| Rosuvastatin, Ezetimibe |
20180114 |
Tintaros Plus, Tablet, 10 mg/10 mg, -, Pack: 30 |
Teva B.V., Нидерландия |
Pabianickie Zaklady Farmaceutyczne Polfa S.A. Полша; Teva Operations Poland, Полша |
16.7 |
3.34 |
20.04 |
6% |
1 |
17.7 |
3.54 |
21.24 |
18% |
3.01 |
20.71 |
4.14 |
24.85 |
|
НСР-19377/02.08.2019 |
02.09.2019 |
02.09.2019 |
Неактивен |
16170 |
| Rosuvastatin, Ezetimibe |
20180115 |
Tintaros Plus, Tablet, 20 mg/10 mg, -, Pack: 30 |
Teva B.V., Нидерландия |
Pabianickie Zaklady Farmaceutyczne Polfa S.A. Полша; Teva Operations Poland, Полша |
16.7 |
3.34 |
20.04 |
6% |
1 |
17.7 |
3.54 |
21.24 |
18% |
3.01 |
20.71 |
4.14 |
24.85 |
|
НСР-19377/02.08.2019 |
02.09.2019 |
02.09.2019 |
Неактивен |
16171 |
| Tirofiban |
20130205 |
Tirofiban-Tchaikapharma, Concentrate for solution for infusion, 0,25mg/ml, 50 ml, Pack: 1 |
Чайкафарма Висококачествените лекарства АД, България |
Чайкафарма Високо-качествените лекарства АД, България |
279.1 |
55.82 |
334.92 |
4% |
10 |
289.1 |
57.82 |
346.92 |
16% |
25 |
314.1 |
62.82 |
376.92 |
|
НСР-1387/10.10.2013 |
25.10.2013 |
25.10.2013 |
Активен |
2148 |
| Dolutegravir |
EU/1/13/892/003 |
Tivicay, Film coated tablet, 10, mg, Pack: 30 |
Viiv Healthcare BV, Нидерландия |
Glaxo Wellcome, S.A., Испания; GlaxoSmithKline Pharmaceuticals S.A., Полша |
187.51 |
37.5 |
225.01 |
4% |
7.5 |
195.01 |
39 |
234.01 |
16% |
25 |
220.01 |
44 |
264.01 |
Корекционно решение НСР-16233/19.07.2018; Промяна на обстоятелства НСР-18022/21.02.2019 |
НСР-13738/12.09.2017; НСР-15730/25.05.2018; НСР-19593/21.08.2019 |
05.09.2019 |
02.10.2019 |
Активен |
15842 |
| Dolutegravir |
EU/1/13/892/003 |
Tivicay, Film coated tablet, 10, mg, Pack: 30 |
Viiv Healthcare BV, Нидерландия |
Glaxo Wellcome, S.A., Испания; GlaxoSmithKline Pharmaceuticals S.A., Полша |
206.4 |
41.28 |
247.68 |
4% |
8.26 |
214.66 |
42.93 |
257.59 |
16% |
25 |
239.66 |
47.93 |
287.59 |
Корекционно решение НСР-16233/19.07.2018; Промяна на обстоятелства НСР-18022/21.02.2019 |
НСР-13738/12.09.2017; НСР-15730/25.05.2018 |
09.06.2018 |
02.04.2019 |
Неактивен |
15842 |
| Dolutegravir |
EU/1/13/892/005 |
Tivicay, Film coated tablet, 25, mg, Pack: 30 |
Viiv Healthcare BV, Нидерландия |
Glaxo Wellcome, S.A., Испания; GlaxoSmithKline Pharmaceuticals S.A., Полша |
468.73 |
93.75 |
562.48 |
4% |
10 |
478.73 |
95.75 |
574.48 |
16% |
25 |
503.73 |
100.75 |
604.48 |
Промяна на обстоятелства НСР-18022/21.02.2019 |
НСР-13738/12.09.2017; НСР-15731/25.05.2018; НСР-19592/21.08.2019 |
05.09.2019 |
02.10.2019 |
Активен |
15843 |
| Dolutegravir |
EU/1/13/892/005 |
Tivicay, Film coated tablet, 25, mg, Pack: 30 |
Viiv Healthcare BV, Нидерландия |
Glaxo Wellcome, S.A., Испания; GlaxoSmithKline Pharmaceuticals S.A., Полша |
515.99 |
103.2 |
619.19 |
4% |
10 |
525.99 |
105.2 |
631.19 |
16% |
25 |
550.99 |
110.2 |
661.19 |
Промяна на обстоятелства НСР-18022/21.02.2019 |
НСР-13738/12.09.2017; НСР-15731/25.05.2018 |
09.06.2018 |
02.04.2019 |
Неактивен |
15843 |
| Dolutegravir |
ЕU/1/13/892/001 |
Tivicay, Film coated tablet, 50, mg, Pack: 30 |
Viiv Healthcare BV, Нидерландия |
Glaxo Wellcome, S.A., Испания |
937.47 |
187.49 |
1124.96 |
4% |
10 |
947.47 |
189.49 |
1136.96 |
16% |
25 |
972.47 |
194.49 |
1166.96 |
Промяна на обстоятелства НСР-18022/21.02.2019 |
НСР-6183/08.05.2015; НСР-11420/13.01.2017 г.; НСР-15351/30.03.2018; НСР-17362/30.11.2018; НСР-19591/21.08.2019 |
05.09.2019 |
02.10.2019 |
Активен |
3922 |
| Dolutegravir |
ЕU/1/13/892/001 |
Tivicay, Film coated tablet, 50, mg, Pack: 30 |
Viiv Healthcare BV, Нидерландия |
Glaxo Wellcome, S.A., Испания |
1025.48 |
205.1 |
1230.58 |
4% |
10 |
1035.48 |
207.1 |
1242.58 |
16% |
25 |
1060.48 |
212.1 |
1272.58 |
Промяна на обстоятелства НСР-18022/21.02.2019 |
НСР-6183/08.05.2015; НСР-11420/13.01.2017 г.; НСР-15351/30.03.2018; НСР-17362/30.11.2018 |
15.12.2018 |
02.04.2019 |
Неактивен |
3922 |
| Dolutegravir |
EU/1/13/892/003 |
Tivicay, Film coated tablet, 10, mg, Pack: 30 |
Viiv Healthcare UK Ltd.,, Обединено Кралство |
Glaxo Wellcome, S.A., Испания; GlaxoSmithKline Pharmaceuticals S.A., Полша |
206.4 |
41.28 |
247.68 |
4% |
8.26 |
214.66 |
42.93 |
257.59 |
16% |
25 |
239.66 |
47.93 |
287.59 |
Корекционно решение НСР-16233/19.07.2018 |
НСР-13738/12.09.2017; НСР-15730/25.05.2018 |
09.06.2018 |
02.09.2018 |
Неактивен |
15842 |
| Dolutegravir |
EU/1/13/892/005 |
Tivicay, Film coated tablet, 25, mg, Pack: 30 |
Viiv Healthcare UK Ltd.,, Обединено Кралство |
Glaxo Wellcome, S.A., Испания; GlaxoSmithKline Pharmaceuticals S.A., Полша |
515.99 |
103.2 |
619.19 |
4% |
10 |
525.99 |
105.2 |
631.19 |
16% |
25 |
550.99 |
110.2 |
661.19 |
|
НСР-13738/12.09.2017; НСР-15731/25.05.2018 |
09.06.2018 |
02.07.2018 |
Неактивен |
15843 |
| Dolutegravir |
ЕU/1/13/892/001 |
Tivicay, Film coated tablet, 50, mg, Pack: 30 |
Viiv Healthcare UK Ltd.,, Обединено Кралство |
Glaxo Wellcome, S.A., Испания |
1025.48 |
205.1 |
1230.58 |
4% |
10 |
1035.48 |
207.1 |
1242.58 |
16% |
25 |
1060.48 |
212.1 |
1272.58 |
|
НСР-6183/08.05.2015; НСР-11420/13.01.2017 г.; НСР-15351/30.03.2018; НСР-17362/30.11.2018 |
15.12.2018 |
02.01.2019 |
Неактивен |
3922 |
| Dolutegravir |
ЕU/1/13/892/001 |
Tivicay, Film coated tablet, 50, mg, Pack: 30 |
Viiv Healthcare UK Ltd.,, Обединено Кралство |
Glaxo Wellcome, S.A., Испания |
1029.96 |
205.99 |
1235.95 |
4% |
10 |
1039.96 |
207.99 |
1247.95 |
16% |
25 |
1064.96 |
212.99 |
1277.95 |
|
НСР-6183/08.05.2015; НСР-11420/13.01.2017 г.; НСР-15351/30.03.2018 |
14.04.2018 |
02.05.2018 |
Неактивен |
3922 |
| Dolutegravir |
EU/1/13/892/003 |
Tivicay, Film coated tablet, 10, mg, Pack: 30 |
Viiv Healthcare UK Ltd.,, Обединено Кралство |
Glaxo Wellcome, S.A., Испания; GlaxoSmithKline Pharmaceuticals S.A., Полша |
206.4 |
41.28 |
247.68 |
4% |
8.26 |
214.66 |
42.93 |
257.59 |
16% |
25 |
239.66 |
47.93 |
287.59 |
|
НСР-13738/12.09.2017; НСР-15730/25.05.2018 |
09.06.2018 |
02.07.2018 |
Неактивен |
15842 |
| Dolutegravir |
EU/1/13/892/003 |
Tivicay, Film coated tablet, 10, mg, Pack: 30 |
Viiv Healthcare UK Ltd.,, Обединено Кралство |
Glaxo Wellcome, S.A., Испания; GlaxoSmithKline Pharmaceuticals S.A., Полша |
212.46 |
42.49 |
254.95 |
4% |
8.5 |
220.96 |
44.19 |
265.15 |
16% |
25 |
245.96 |
49.19 |
295.15 |
|
НСР-13738/12.09.2017 |
27.09.2017 |
02.10.2017 |
Неактивен |
15842 |
| Dolutegravir |
EU/1/13/892/005 |
Tivicay, Film coated tablet, 25, mg, Pack: 30 |
Viiv Healthcare UK Ltd.,, Обединено Кралство |
Glaxo Wellcome, S.A., Испания; GlaxoSmithKline Pharmaceuticals S.A., Полша |
531.13 |
106.23 |
637.36 |
4% |
10 |
541.13 |
108.23 |
649.36 |
16% |
25 |
566.13 |
113.23 |
679.36 |
|
НСР-13738/12.09.2017 |
27.09.2017 |
02.10.2017 |
Неактивен |
15843 |
| Dolutegravir |
ЕU/1/13/892/001 |
Tivicay, Film coated tablet, 50, mg, Pack: 30 |
Viiv Healthcare UK Ltd.,, Обединено Кралство |
Glaxo Wellcome, S.A., Испания |
1031.7 |
206.34 |
1238.04 |
4% |
10 |
1041.7 |
208.34 |
1250.04 |
16% |
25 |
1066.7 |
213.34 |
1280.04 |
|
НСР-6183/08.05.2015; НСР-11420/13.01.2017 г. |
28.01.2017 |
02.02.2017 |
Неактивен |
3922 |
| Dolutegravir |
ЕU/1/13/892/001 |
Tivicay, Film coated tablet, 50, mg, Pack: 30 |
Viiv Healthcare UK Ltd.,, Обединено Кралство |
Glaxo Wellcome, S.A., Испания |
1031.7 |
206.34 |
1238.04 |
4% |
10 |
1041.7 |
208.34 |
1250.04 |
16% |
25 |
1066.7 |
213.34 |
1280.04 |
|
НСР-6183/08.05.2015; НСР-11420/13.01.2017 г. |
02.02.2017 |
02.02.2017 |
Неактивен |
3922 |
| Dolutegravir |
ЕU/1/13/892/001 |
Tivicay, Film coated tablet, 50, mg, Pack: 30 |
Viiv Healthcare UK Ltd.,, Обединено Кралство |
Glaxo Wellcome, S.A., Испания |
1031.95 |
206.39 |
1238.34 |
4% |
10 |
1041.95 |
208.39 |
1250.34 |
16% |
25 |
1066.95 |
213.39 |
1280.34 |
|
НСР-6183/08.05.2015 |
25.05.2015 |
25.05.2015 |
Неактивен |
3922 |
| Dolutegravir |
ЕU/1/13/892/001 |
Tivicay, Film coated tablet, 50, mg, Pack: 30 |
Viiv Healthcare UK Ltd.,, Обединено Кралство |
Glaxo Wellcome, S.A., Испания |
1118.19 |
223.64 |
1341.83 |
4% |
10 |
1128.19 |
225.64 |
1353.83 |
16% |
25 |
1153.19 |
230.64 |
1383.83 |
|
НСР-4729/29.09.2014 |
29.09.2014 |
29.09.2014 |
Неактивен |
3922 |
| Tizanidine |
20070126 |
Tizanidine Teva, Tablet, 2, mg, Pack: 50 |
Teva B.V., Нидерландия |
Teva UK Ltd., UK; Pharmachemie B.V., The Netherlands; TEVA Pharmaceutical Works Private Limited company, Hungary; TEVA Pharmaceutical Works Private Limited company, Hungary |
6.14 |
1.23 |
7.37 |
7% |
0.43 |
6.57 |
1.31 |
7.88 |
20% |
1.23 |
7.8 |
1.56 |
9.36 |
промяна на обстоятелства решение НСР-7091/15.09.2015; НСР-17760/17.01.2019 |
КЦРР-1208/13.08.2012 |
28.08.2012 |
02.02.2019 |
Активен |
1327 |
| Tizanidine |
20070126 |
Tizanidine Teva, Tablet, 2, mg, Pack: 50 |
Тева Фармасютикълс България ЕООД, България |
Teva UK Ltd., UK; Pharmachemie B.V., The Netherlands; TEVA Pharmaceutical Works Private Limited company, Hungary; TEVA Pharmaceutical Works Private Limited company, Hungary |
6.14 |
1.23 |
7.37 |
7% |
0.43 |
6.57 |
1.31 |
7.88 |
20% |
1.23 |
7.8 |
1.56 |
9.36 |
промяна на обстоятелства решение НСР-7091/15.09.2015 |
КЦРР-1208/13.08.2012 |
28.08.2012 |
28.08.2012 |
Неактивен |
1327 |
| Tizanidine |
20070127 |
Tizanidine Teva, Film coated tablet, 4, mg, Pack: 50 |
Teva B.V., Нидерландия |
Teva UK Ltd., England; Pharmachemie BV., The Netherlands; Teva Pharmaceutical Works private Limited Company, Hungary; Teva Pharmaceutical Works private Limited Company, Hungary |
21.34 |
4.27 |
25.61 |
6% |
1.28 |
22.62 |
4.52 |
27.14 |
18% |
3.84 |
26.46 |
5.29 |
31.75 |
промяна на обстоятелства решение НСР-8590/24.03.2016; НСР-17759/17.01.2019 |
НСР-9022/21.04.2016 |
07.05.2016 |
02.02.2019 |
Активен |
420 |
| Tizanidine |
20070127 |
Tizanidine Teva, Film coated tablet, 4, mg, Pack: 50 |
Тева Фармасютикълс България ЕООД, България |
Teva UK Ltd., England; Pharmachemie BV., The Netherlands; Teva Pharmaceutical Works private Limited Company, Hungary; Teva Pharmaceutical Works private Limited Company, Hungary |
21.34 |
4.27 |
25.61 |
6% |
1.28 |
22.62 |
4.52 |
27.14 |
18% |
3.84 |
26.46 |
5.29 |
31.75 |
промяна на обстоятелства решение НСР-8590/24.03.2016. |
НСР-9022/21.04.2016 |
07.05.2016 |
02.06.2016 |
Неактивен |
420 |
| Tizanidine |
20070127 |
Tizanidine Teva, Film coated tablet, 4, mg, Pack: 50 |
Тева Фармасютикълс България ЕООД, България |
Teva UK Ltd., England; Pharmachemie BV., The Netherlands; Teva Pharmaceutical Works private Limited Company, Hungary; Teva Pharmaceutical Works private Limited Company, Hungary |
21.34 |
4.27 |
25.61 |
6% |
1.28 |
22.62 |
4.52 |
27.14 |
18% |
3.84 |
26.46 |
5.29 |
31.75 |
промяна на обстоятелства решение НСР-8590/24.03.2016. |
КЦ-400/07.01.2009; НСР-9022/21.04.2016 |
02.06.2016 |
02.06.2016 |
Неактивен |
420 |